LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.

    Qian, Yu / Galan-Cobo, Ana / Guijarro, Irene / Dang, Minghao / Molkentine, David / Poteete, Alissa / Zhang, Fahao / Wang, Qi / Wang, Jing / Parra, Edwin / Panda, Apekshya / Fang, Jacy / Skoulidis, Ferdinandos / Wistuba, Ignacio I / Verma, Svena / Merghoub, Taha / Wolchok, Jedd D / Wong, Kwok-Kin / DeBerardinis, Ralph J /
    Minna, John D / Vokes, Natalie I / Meador, Catherine B / Gainor, Justin F / Wang, Linghua / Reuben, Alexandre / Heymach, John V

    Cancer cell

    2023  Volume 41, Issue 7, Page(s) 1363–1380.e7

    Abstract: Inactivating STK11/LKB1 mutations are genomic drivers of primary resistance to immunotherapy in KRAS-mutated lung adenocarcinoma (LUAD), although the underlying mechanisms remain unelucidated. We find that LKB1 loss results in enhanced lactate production ...

    Abstract Inactivating STK11/LKB1 mutations are genomic drivers of primary resistance to immunotherapy in KRAS-mutated lung adenocarcinoma (LUAD), although the underlying mechanisms remain unelucidated. We find that LKB1 loss results in enhanced lactate production and secretion via the MCT4 transporter. Single-cell RNA profiling of murine models indicates that LKB1-deficient tumors have increased M2 macrophage polarization and hypofunctional T cells, effects that could be recapitulated by the addition of exogenous lactate and abrogated by MCT4 knockdown or therapeutic blockade of the lactate receptor GPR81 expressed on immune cells. Furthermore, MCT4 knockout reverses the resistance to PD-1 blockade induced by LKB1 loss in syngeneic murine models. Finally, tumors from STK11/LKB1 mutant LUAD patients demonstrate a similar phenotype of enhanced M2-macrophages polarization and hypofunctional T cells. These data provide evidence that lactate suppresses antitumor immunity and therapeutic targeting of this pathway is a promising strategy to reversing immunotherapy resistance in STK11/LKB1 mutant LUAD.
    MeSH term(s) Animals ; Mice ; Adenocarcinoma of Lung/genetics ; Adenocarcinoma of Lung/therapy ; Adenocarcinoma of Lung/metabolism ; Lactates/metabolism ; Lactates/pharmacology ; Lactates/therapeutic use ; Lung Neoplasms/therapy ; Lung Neoplasms/drug therapy ; Macrophages ; Mutation ; Protein Serine-Threonine Kinases/genetics ; Protein Serine-Threonine Kinases/metabolism
    Chemical Substances Lactates ; Protein Serine-Threonine Kinases (EC 2.7.11.1) ; Slc16a4 protein, mouse
    Language English
    Publishing date 2023-06-15
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2078448-X
    ISSN 1878-3686 ; 1535-6108
    ISSN (online) 1878-3686
    ISSN 1535-6108
    DOI 10.1016/j.ccell.2023.05.015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy.

    Revach, Or-Yam / Cicerchia, Angelina M / Shorer, Ofir / Petrova, Boryana / Anderson, Seth / Park, Joshua / Chen, Lee / Mehta, Arnav / Wright, Samuel J / McNamee, Niamh / Tal-Mason, Aya / Cattaneo, Giulia / Tiwari, Payal / Xie, Hongyan / Sweere, Johanna M / Cheng, Li-Chun / Sigal, Natalia / Enrico, Elizabeth / Miljkovic, Marisa /
    Evans, Shane A / Nguyen, Ngan / Whidden, Mark E / Srinivasan, Ramji / Spitzer, Matthew H / Sun, Yi / Sharova, Tatyana / Lawless, Aleigha R / Michaud, William A / Rasmussen, Martin Q / Fang, Jacy / Palin, Claire A / Chen, Feng / Wang, Xinhui / Ferrone, Cristina R / Lawrence, Donald P / Sullivan, Ryan J / Liu, David / Sachdeva, Uma M / Sen, Debattama R / Flaherty, Keith T / Manguso, Robert T / Bod, Lloyd / Kellis, Manolis / Boland, Genevieve M / Yizhak, Keren / Yang, Jiekun / Kanarek, Naama / Sade-Feldman, Moshe / Hacohen, Nir / Jenkins, Russell W

    bioRxiv : the preprint server for biology

    2024  

    Abstract: A central problem in cancer immunotherapy with immune checkpoint blockade (ICB) is the development of resistance, which affects 50% of patients with metastatic ... ...

    Abstract A central problem in cancer immunotherapy with immune checkpoint blockade (ICB) is the development of resistance, which affects 50% of patients with metastatic melanoma
    Language English
    Publishing date 2024-03-26
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2024.02.12.579184
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: DrugMap: A quantitative pan-cancer analysis of cysteine ligandability.

    Takahashi, Mariko / Chong, Harrison B / Zhang, Siwen / Yang, Tzu-Yi / Lazarov, Matthew J / Harry, Stefan / Maynard, Michelle / Hilbert, Brendan / White, Ryan D / Murrey, Heather E / Tsou, Chih-Chiang / Vordermark, Kira / Assaad, Jonathan / Gohar, Magdy / Dürr, Benedikt R / Richter, Marianne / Patel, Himani / Kryukov, Gregory / Brooijmans, Natasja /
    Alghali, Aliyu Sidi Omar / Rubio, Karla / Villanueva, Antonio / Zhang, Junbing / Ge, Maolin / Makram, Farah / Griesshaber, Hanna / Harrison, Drew / Koglin, Ann-Sophie / Ojeda, Samuel / Karakyriakou, Barbara / Healy, Alexander / Popoola, George / Rachmin, Inbal / Khandelwal, Neha / Neil, Jason R / Tien, Pei-Chieh / Chen, Nicholas / Hosp, Tobias / van den Ouweland, Sanne / Hara, Toshiro / Bussema, Lillian / Dong, Rui / Shi, Lei / Rasmussen, Martin Q / Domingues, Ana Carolina / Lawless, Aleigha / Fang, Jacy / Yoda, Satoshi / Nguyen, Linh Phuong / Reeves, Sarah Marie / Wakefield, Farrah Nicole / Acker, Adam / Clark, Sarah Elizabeth / Dubash, Taronish / Kastanos, John / Oh, Eugene / Fisher, David E / Maheswaran, Shyamala / Haber, Daniel A / Boland, Genevieve M / Sade-Feldman, Moshe / Jenkins, Russell W / Hata, Aaron N / Bardeesy, Nabeel M / Suvà, Mario L / Martin, Brent R / Liau, Brian B / Ott, Christopher J / Rivera, Miguel N / Lawrence, Michael S / Bar-Peled, Liron

    Cell

    2024  

    Abstract: Cysteine-focused chemical proteomic platforms have accelerated the clinical development of covalent inhibitors for a wide range of targets in cancer. However, how different oncogenic contexts influence cysteine targeting remains unknown. To address this ... ...

    Abstract Cysteine-focused chemical proteomic platforms have accelerated the clinical development of covalent inhibitors for a wide range of targets in cancer. However, how different oncogenic contexts influence cysteine targeting remains unknown. To address this question, we have developed "DrugMap," an atlas of cysteine ligandability compiled across 416 cancer cell lines. We unexpectedly find that cysteine ligandability varies across cancer cell lines, and we attribute this to differences in cellular redox states, protein conformational changes, and genetic mutations. Leveraging these findings, we identify actionable cysteines in NF-κB1 and SOX10 and develop corresponding covalent ligands that block the activity of these transcription factors. We demonstrate that the NF-κB1 probe blocks DNA binding, whereas the SOX10 ligand increases SOX10-SOX10 interactions and disrupts melanoma transcriptional signaling. Our findings reveal heterogeneity in cysteine ligandability across cancers, pinpoint cell-intrinsic features driving cysteine targeting, and illustrate the use of covalent probes to disrupt oncogenic transcription-factor activity.
    Language English
    Publishing date 2024-04-17
    Publishing country United States
    Document type Journal Article
    ZDB-ID 187009-9
    ISSN 1097-4172 ; 0092-8674
    ISSN (online) 1097-4172
    ISSN 0092-8674
    DOI 10.1016/j.cell.2024.03.027
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: DrugMap: A quantitative pan-cancer analysis of cysteine ligandability.

    Takahashi, Mariko / Chong, Harrison B / Zhang, Siwen / Lazarov, Matthew J / Harry, Stefan / Maynard, Michelle / White, Ryan / Murrey, Heather E / Hilbert, Brendan / Neil, Jason R / Gohar, Magdy / Ge, Maolin / Zhang, Junbing / Durr, Benedikt R / Kryukov, Gregory / Tsou, Chih-Chiang / Brooijmans, Natasja / Alghali, Aliyu Sidi Omar / Rubio, Karla /
    Vilanueva, Antonio / Harrison, Drew / Koglin, Ann-Sophie / Ojeda, Samuel / Karakyriakou, Barbara / Healy, Alexander / Assaad, Jonathan / Makram, Farah / Rachman, Inbal / Khandelwal, Neha / Tien, Pei-Chieh / Popoola, George / Chen, Nicholas / Vordermark, Kira / Richter, Marianne / Patel, Himani / Yang, Tzu-Yi / Griesshaber, Hanna / Hosp, Tobias / van den Ouweland, Sanne / Hara, Toshiro / Bussema, Lily / Dong, Rui / Shi, Lei / Rasmussen, Martin Q / Domingues, Ana Carolina / Lawless, Aleigha / Fang, Jacy / Yoda, Satoshi / Nguyen, Linh Phuong / Reeves, Sarah Marie / Wakefield, Farrah Nicole / Acker, Adam / Clark, Sarah Elizabeth / Dubash, Taronish / Fisher, David E / Maheswaran, Shyamala / Haber, Daniel A / Boland, Genevieve / Sade-Feldman, Moshe / Jenkins, Russel / Hata, Aaron / Bardeesy, Nabeel / Suva, Mario L / Martin, Brent / Liau, Brian / Ott, Christopher / Rivera, Miguel N / Lawrence, Michael S / Bar-Peled, Liron

    bioRxiv : the preprint server for biology

    2023  

    Abstract: Cysteine-focused chemical proteomic platforms have accelerated the clinical development of covalent inhibitors of a wide-range of targets in cancer. However, how different oncogenic contexts influence cysteine targeting remains unknown. To address this ... ...

    Abstract Cysteine-focused chemical proteomic platforms have accelerated the clinical development of covalent inhibitors of a wide-range of targets in cancer. However, how different oncogenic contexts influence cysteine targeting remains unknown. To address this question, we have developed
    Language English
    Publishing date 2023-10-23
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.10.20.563287
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top